Article
Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients
Author(s):
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
